Clinical Study on Veloderm for the Treatment of Split-thickness Skin Graft Donor Sites

January 24, 2012 updated by: Lee's Pharmaceutical Limited

A Clinical Study to Evaluate the Safety and Efficacy on Veloderm (a Crystalline Cellulose Simple Occlusive Dressing) for the Split-thickness Skin Graft Donor Sites in Burn and Plastic Surgery

This study is a multi-center, randomized, open and paralleled positive control study for evaluating the safety and efficacy of Veloderm in treatment of split-thickness skin graft donor sites. The result implies that Veloerm can do it better than Vaseline gauze in accelerating and promoting wound healing of skin graft donor sites. The present study have indicated that high permeability of Veloderm dressing to oxygen and water vapor.

Study Overview

Detailed Description

The rational oxygen permeability of Veloderm dressing also provides a good environment for wound healing. Therefore, it can be as a temporary skin substitute in the case of missing epidermis to play a role, in order to provide an ideal environment for wound epithelialization. As regards safety, 1 adverse reaction occured in test group. It shows effusion under the dressing mild inflammatory infiltration on the wound edge. After the dressing was changed and the effusion was drained, the patient was relieved. As Veloderm dressing itself has no direct anti-inflammatory effects, clinical application as appropriate can plus other anti-infective drugs in accordance with patient conditions. In conclusion, Veloderm is a safe and effective dressing to accelerate the healing of donor sites in burn and plastic surgery. Veloderm can be used as a temporary skin substitute in case of damage of skin or loss of superficial epidermal (such as burns, wounds, abrasions, ulcers, sores and auto-graft donor areas).

Study Type

Interventional

Enrollment (Actual)

96

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-65 years
  • Male or female patients
  • Skin lesions or losses by burns, plastic surgery, sores, abrasions, donor graft areas and after debridement of chronic wounds
  • The area of skin loss or burn surface is less than 50% of total area of body surface
  • Subject undergoing first skin harvest 0.25-0.35mm and donor site having a surface area>100cm2
  • Subject who is willing to participate in the trial and to sign the informed consent form.

Exclusion Criteria:

  • Area of skin loss or burn surface is larger than 50% of total area of body surface
  • Electrical burns or chemical burns
  • Burns complicated by combined injury
  • Test wound needs drugs that may affect wound healing
  • Subject who has a known hypersensitivity to hemycellulose
  • Contraindication to the use of semi occlusive dressing
  • Pregnant or lactating subject
  • Any severe disease which in the Investigator's judgement might interfere with study evaluations or threaten patient's safety
  • Subject who has chronic renal disease or renal inadequacy, or serum creatinine is more than twice the upper limit of normal
  • Subject who has a definite liver disease, TBil or AST, ALT is more than twice the upper limit of normal
  • Subject with active hemorrhoea or shock or visceral injury; Subject who has participated in this clinical study or other clinical studies within 3 months
  • Subject with mental impairment limiting the ability to comply with study requirements; Subject undergone chronic treatment with immunosuppressants, antineoplastic drugs and corticosteroids for a long time
  • Subject who has not signed the informed consent form.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Veloderm
A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
Other Names:
  • Veloderm
Placebo Comparator: Vaseline
External use

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Response Criteria
Time Frame: 3 months
To observate the efficacy measurements, vital signs, laboratory examinations and adverse events
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation criteria
Time Frame: 6 months
To evaluate the time to complete epithilization, effectiveness, presence of exudates, presence of prei-lesional erythema, pain intensity and laboratory examination
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2008

Primary Completion (Actual)

April 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

September 14, 2010

First Submitted That Met QC Criteria

January 13, 2012

First Posted (Estimate)

January 19, 2012

Study Record Updates

Last Update Posted (Estimate)

January 25, 2012

Last Update Submitted That Met QC Criteria

January 24, 2012

Last Verified

January 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZHAOKE-VL2010

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Split-thickness Skin Graft Donor Sites

Clinical Trials on Crystalline cellulose simple occlusive dressing

Subscribe